Real world study in EGFR mutated unresectable nonsmall cell lung cancer patients.

Not Applicable

Recruiting

• Conditions: on small cell lung cancer; Solid tumors, Lung cancer, Non small cell lung cancer, Genetic mutation, EGFR; D002289

• Registration Number: JPRN-jRCT1030230162
• Lead Sponsor: ICCC: 3H Medi Solution Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-06-24
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Histologically and lab-confirmed diagnosis of stage III NSCLC
-Histologically and lab-confirmed diagnosis of stage I-II NSCLC
-Tumor harbors at least 1 of the 2 common EGFRms: Exon 19 deletion or L858R

Exclusion Criteria

-Evidence of other cancer diagnoses (apart from basal cell carcinoma) within one year prior to the index diagnosis date
-Participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2016 onward

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rwPFS

Secondary Outcome Measures

Name	Time	Method
-Demographic and clinical characteristics<br>-Treatment patterns<br>-Percentage of patients tested for mutations, testing methods and results<br>-rwOS<br>-rwTTNTD